Emcure Pharmaceuticals reported a 16.6% year-on-year increase in revenue from operations to ₹9,204 crore for the financial year ended March 31, 2026. Profit after tax for the year rose 33.1% to ₹941 crore, with adjusted PAT growing 40.9% to ₹1,008 crore. The growth was driven by robust performance across international markets, which grew 22.2% to ₹5,177 crore, while domestic revenue increased 10% to ₹4,027 crore.

The company’s operational efficiency improved significantly, with EBITDA growing 21.8% to ₹1,789 crore. EBITDA margins expanded by 83 basis points to 19.4%, driven by productivity enhancements and the scaling of in-house products. Return on capital employed (ROCE) improved by 180 basis points to 23.8%. The net profit margin stood at 10.2%, an increase of 127 basis points from the previous year.

Financial Performance FY26

Segment and Regional Growth

International business contributed significantly to the top line, with Europe growing 25.5% to ₹1,850 crore and Canada increasing 18.7% to ₹1,487 crore. The Rest of the World (RoW) segment reported a 21.8% growth to ₹1,840 crore. The domestic business grew in line with the Indian Pharmaceutical Market (IPM), led by strong performance in Cardiac, CNS, and Oncology therapies.

Strategic Developments

Emcure strengthened its portfolio through strategic in-licensing partnerships with Sanofi, Novo Nordisk, and Roche. The company acquired full control of Zuventus Healthcare for ₹724.9 crore to consolidate domestic operations. Additionally, its UK subsidiary, Tillomed Laboratories, signed a £19.7 million asset purchase agreement. The company’s pipeline includes differentiated products across biologics, complex injectables, and novel drug delivery systems (NDDS).

Balance Sheet and Cash Flow

The company’s net debt as of March 31, 2026, stood at ₹1,054 crore, against gross debt of ₹1,204 crore. Cash generated from operations increased to ₹944 crore in FY26 from ₹852 crore in the previous year. Net cash used for investing activities was ₹1,193 crore, primarily due to the acquisition of the Zuventus Healthcare minority interest and capital expenditure.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE168P01015/9e03e34348694981.pdf

Emcure Pharmaceuticals witnessed a notable block trade on the National Stock Exchange (NSE) during the pre-open session. The transaction was executed at a price of ₹1,700 per share, aggregating to a total deal value of ₹211.53 crore.

Block Trade Details

The block trade involved approximately 12,44,279 shares of Emcure Pharmaceuticals, transacted in the pre-open segment on the NSE. The following table summarizes the key parameters of the transaction:

Block trades of this scale are typically executed between large institutional participants and are reported separately from regular market transactions. The pre-open session execution indicates the deal was arranged prior to the commencement of normal trading hours.